欧盟/欧洲经济区HPV疫苗接种计划的健康状况

SURVEILLANCE & MONITORING The State of Health of HPV vaccinationprogrammes in the EU/EEA This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated byKaram Adel andNathalie Nicolay. Contributing authorsKaram Adel, Nathalie Nicolay, Silvia Funke, Phyo Myint, Kate Olsson, Andrea Wuerz. AcknowledgementsThe following experts responded to the ECDC survey and reported data on HPV vaccination programmes:Austria: Jiale Lin (Federal Ministry of Labour, Social Affairs, Health, Care and Consumer Protection), Maria Paulke Korinek(Federal Ministry of Labour, Social Affairs, Health, Care and Consumer Protection);Belgium:Laura Cornelissen(Sciensano),Cato Dambre (Sciensano),Hélène De Pauw (Sciensano);Bulgaria:Nadezhda Vladimirova (NationalCentre of Infectious and Parasitic Diseases (NCIPD));Croatia:Bernard Kaić(Croatian Institute of Public Health),Vesna Višekruna Vučina (Croatia Institute of Public Health);Cyprus: Anna Papandreou Kazamia (Ministry ofHealth);Denmark:Ida Rask Moustsen-Helms (Statens Serum Institut);Estonia:Keiti Aren (Health Board),IrinaFilippova (Health Board);France: Anne-Sophie BARRET (SantéPublique France), Laure Fonteneau (Santé publiqueFrance);Finland:Nina Strömberg (The Finnish Institute for Health and Welfare);Germany: Anja Takla (RobertKoch Institute);Greece: Stella Vorre (National Public Health Organization (NPHO));Hungary: ZsuzsannaMolnár(National Centre for Public Health and Pharmacy);Iceland: Kamilla Sigríður Jósefsdóttir (Centre for HealthSecurity and Communicable Disease Control);Ireland:Sarah Gee (Health Protection Surveillance Centre);Italy:Anna Caraglia (Ministerodella Salute),Cristian Ferrao (Ministero della Salute);Liechtenstein: Esther Walser-Domjan (Amt für Gesundheit);Lithuania:Nerija Kuprevičienė (Lietuvos Respublikos sveikatos apsaugosministerija);Luxembourg: Silvana Masi (Ministère de la Santé et de la Sécurité sociale), Anne Vergison(Ministèrede la Santé et de la Sécurité sociale);Malta: Tanya Melillo (Department for Health Regulation);Netherlands:Alies van Lier (Rijksinstituut voor Volksgezondheid en Milieu (RIVM)),JannekeDuijster(Rijksinstituut voorVolksgezondheid en Milieu (RIVM));Norway:Evy Therese Dvergsdal (Norwegian Institute of Public Health),Jeanette Stålcrantz (Norwegian Institute of Public Health);Poland:Iwona Paradowska-Stankiewicz (Department ofEpidemiology of Infectious Diseases and Surveillance)Iwona Paradowska-Stankiewicz (Department of Epidemiologyof Infectious Diseases and Surveillance, National Institute of Public Health NIH-National ResearchInstitute);Portugal: Raquel Eusébio (Directorate-General of Health), Natália Pereira (Directorate-General of Health), Bruno Alves (Directorate-General of Health), Joana Roque (Directorate-General of Health), Susana Cardoso (Directorate-General of Health), Patrícia Valentim (Directorate-General of Health);Romania:Aurora Stanescu (NationalInstitute of Public Health);Slovakia: Helena Hudecová (Public Health Authority of the Slovak Republic);Slovenia:Nadja Sinkovec Zorko(National Institute of Public Health),Marta Grgič Vitek (National Institute of Public Health);Spain:Carmen Olmedo (Ministry of Health);Sweden: Hélène Englund (Public Health Agency ofSweden). Suggested citation: European Centre for Disease Prevention and Control.The State of Health of HPV vaccinationprogrammes in the EU/EEA.Stockholm: ECDC;2026. Contents The State of Health of HPV vaccination programmes in the EU/EEA................................................................................iAbbreviations..............................................................................................................................................................ivExecutive summary......................................................................................................................................................1Background and context...............................................................................................................................................4Aims and objectives of this report.................................................................................................................................4Methods and sources of data........................................................................................................................................5Burden of HPV infections and HPV-related cancers in the EU/EEA..................................................................................6HPV vaccines and historical developments.....................................................................................................................8HPV vaccination policies and programmes.....................................................................................................................8HPV vaccination................................................................................................................................................